Romidepsin

TERMINATED · PHASE1, PHASE2 · Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma

Lack of funding and recruitment complications caused by COVID-19

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.